Clinical variables in patients with CEBPAbZIP-inf and CEBPAother mutations
| . | CEBPAwt n = 4468 . | CEBPAbZIP-inf n = 157 . | CEBPAother n = 83 . | P (adj.) . |
|---|---|---|---|---|
| Age in years, median (IQR) | 57 (46-67) | 46 (36-57) | 62 (55-69) | <.001 |
| Sex, n (%) | ||||
| Female | 2170 (49) | . 76 (48) | 42 (51) | .885 |
| Male | 2298 (51) | 81 (52) | 41 (49) | |
| AML type, n (%) | ||||
| De novo | 3510 (78) | 149 (96) | 69 (83) | <.001 |
| sAML | 630 (14) | 5 (3) | 9 (11) | |
| tAML | 328 (7) | 2 (1) | 5 (6) | |
| FAB subtype, n (%) | ||||
| M0 | 223 (5) | 1 (1) | / | <.001 |
| M1/M2 | 2040 (46) | 127 (81) | 53 (65) | |
| M4-M7 | 1535 (34) | 22 (14) | 20 (24) | |
| Unknown | 670 (15) | 7 (4) | 9 (11) | |
| Laboratory, median (IQR) | ||||
| BM blasts in % | 60 (38-80) | 64 (50-78) | 62 (43.5-78) | .853 |
| CD34-positivity in % | 16 (2-47) | 51 (29-75.2) | 34 (6.6-72.2) | <.001 |
| WBC in 109/l | 11.7 (3-45.7) | 25 (9.2-70) | 14.7 (4.6-53.4) | .001 |
| LDH in U/l | 412.9 (272-727) | 445 (295-758) | 449 (296-601) | .242 |
| Treatment, n (%) | ||||
| Primary allo-HCT | 747 (17) | 52 (33) | 5 (6) | <.001 |
| Salvage allo-HCT | 915 (20) | 21 (13) | 16 (19) | .209 |
| . | CEBPAwt n = 4468 . | CEBPAbZIP-inf n = 157 . | CEBPAother n = 83 . | P (adj.) . |
|---|---|---|---|---|
| Age in years, median (IQR) | 57 (46-67) | 46 (36-57) | 62 (55-69) | <.001 |
| Sex, n (%) | ||||
| Female | 2170 (49) | . 76 (48) | 42 (51) | .885 |
| Male | 2298 (51) | 81 (52) | 41 (49) | |
| AML type, n (%) | ||||
| De novo | 3510 (78) | 149 (96) | 69 (83) | <.001 |
| sAML | 630 (14) | 5 (3) | 9 (11) | |
| tAML | 328 (7) | 2 (1) | 5 (6) | |
| FAB subtype, n (%) | ||||
| M0 | 223 (5) | 1 (1) | / | <.001 |
| M1/M2 | 2040 (46) | 127 (81) | 53 (65) | |
| M4-M7 | 1535 (34) | 22 (14) | 20 (24) | |
| Unknown | 670 (15) | 7 (4) | 9 (11) | |
| Laboratory, median (IQR) | ||||
| BM blasts in % | 60 (38-80) | 64 (50-78) | 62 (43.5-78) | .853 |
| CD34-positivity in % | 16 (2-47) | 51 (29-75.2) | 34 (6.6-72.2) | <.001 |
| WBC in 109/l | 11.7 (3-45.7) | 25 (9.2-70) | 14.7 (4.6-53.4) | .001 |
| LDH in U/l | 412.9 (272-727) | 445 (295-758) | 449 (296-601) | .242 |
| Treatment, n (%) | ||||
| Primary allo-HCT | 747 (17) | 52 (33) | 5 (6) | <.001 |
| Salvage allo-HCT | 915 (20) | 21 (13) | 16 (19) | .209 |
Bold P-values indicate statically significant results.
BM, bone marrow; LDH, lactate dehydrogenase; FAB, French-American-British; MRC, medical research council.